Wednesday, July 8, 2026

biotech · Breast Cancer · Sarcoma,Soft Tissue · INTS

INTENSITY THERAPEUTICS

INTENSITY THERAPEUTICS clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Shelton, USA HQ
2012 Founded
12 Employees
Public company Type
INTS · NYSE Ticker
Company details
Status
Public
HQ
Shelton, USA
Founded
2012
Employees
12
Programs
6
Drugs
9
Patents
3
Intelligence · Clinical Programs

INTENSITY THERAPEUTICS projects

6 ClinicalTrials.gov programs sponsored by INTENSITY THERAPEUTICS.

INTENSITY THERAPEUTICS has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Sarcoma,Soft Tissue

    phase 3 small molecule active

    1 trial
  2. IT-03

    INTENSITY THERAPEUTICS, INC.

    liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma

    phase 3 small molecule active

    1 trial
  3. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Breast Cancer

    phase 2 small molecule active

    2 trials
  4. JIN-A02

    INTENSITY THERAPEUTICS, INC.

    EGFR Mutant Advanced Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  5. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial
  6. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Covid19

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does INTENSITY THERAPEUTICS have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.